Microglia in Alzheimer's disease: A multifaceted relationship
1Neuroscience Laboratory, CHU de Québec Research Center (CHUL), Department of Molecular Medicine, Faculty of Medicine, Laval University, Canada.
Brain, Behavior, and Immunity
|August 9, 2015
Summary
Microglia, the brain's immune cells, play a crucial role in Alzheimer's disease (AD) by responding to amyloid-beta plaques. Their exact role in AD pathology and treatment remains under investigation, highlighting the need for further research.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles.
- Neuroinflammation, driven by microglia, is increasingly recognized as a key factor in AD pathogenesis.
- Microglia are the brain's resident immune cells, acting as sentinels that respond to homeostatic alterations.
Purpose of the Study:
- To review the current understanding of microglia's role in Alzheimer's disease pathology.
- To discuss the implications of microglial activity in AD treatment strategies.
- To explore the emerging role of monocytes in the context of AD.
Main Methods:
- Literature review of experimental evidence on microglia and AD.
- Analysis of studies investigating microglial activation and response to Aβ.
- Discussion of conflicting findings regarding microglial modulation in AD.
Main Results:
- Microglia surround and can internalize Aβ aggregates, but their precise contribution to AD is debated.
- Microglial activation involves phenotypic changes and responses including phagocytosis and factor secretion.
- Conflicting experimental results complicate the targeting of microglial activity for AD treatment.
Conclusions:
- Microglia are central players in AD neuroinflammation, with their precise role in disease progression and as therapeutic targets still under active investigation.
- Understanding microglial dynamics and their interaction with Aβ is critical for developing effective AD treatments.
- Further research is needed to clarify the complex functions of microglia and monocytes in Alzheimer's disease.
Related Concept Videos
01:26Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K